MA33060B1 - Formulations galéniques de composés organiques - Google Patents

Formulations galéniques de composés organiques

Info

Publication number
MA33060B1
MA33060B1 MA34114A MA34114A MA33060B1 MA 33060 B1 MA33060 B1 MA 33060B1 MA 34114 A MA34114 A MA 34114A MA 34114 A MA34114 A MA 34114A MA 33060 B1 MA33060 B1 MA 33060B1
Authority
MA
Morocco
Prior art keywords
tablet
central portion
pharmacy
capsules
organic compounds
Prior art date
Application number
MA34114A
Other languages
Arabic (ar)
English (en)
Inventor
Sabine Desset-Brèthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33060B1 publication Critical patent/MA33060B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une forme de dosage unitaire solide pour administration orale sous la forme d'un comprimé, doté d'une partie centrale et d'un enrobage externe. Ladite partie centrale dudit comprimé comprend une quantité thérapeutiquement efficace d'Aliskiren, ou un sel pharmaceutiquement acceptable de celui-ci, et l'enrobage externe se présente sous la forme d'un revêtement de film qui possède des propriétés de masquage de goût et/ou une fonctionnalité de libération contrôlée. De préférence, le comprimé avec partie centrale fait partie d'un système multiparticulaire, et est en particulier un mini-comprimé. La forme de dosage oral solide est particulièrement adaptée à un usage pédiatrique.
MA34114A 2009-01-28 2010-01-27 Formulations galéniques de composés organiques MA33060B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA33060B1 true MA33060B1 (fr) 2012-02-01

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34114A MA33060B1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Country Status (27)

Country Link
US (1) US20110287100A1 (fr)
EP (1) EP2391345B1 (fr)
JP (1) JP2012516299A (fr)
KR (1) KR20110117199A (fr)
CN (1) CN102300558A (fr)
AR (1) AR075179A1 (fr)
AU (1) AU2010209787B2 (fr)
BR (1) BRPI1007452A2 (fr)
CA (1) CA2749531A1 (fr)
CL (1) CL2011001817A1 (fr)
CO (1) CO6400184A2 (fr)
EC (1) ECSP11011289A (fr)
ES (1) ES2525648T3 (fr)
IL (1) IL213918A0 (fr)
MA (1) MA33060B1 (fr)
MX (1) MX2011007779A (fr)
MY (1) MY153852A (fr)
NZ (1) NZ593622A (fr)
PE (1) PE20110943A1 (fr)
PL (1) PL2391345T3 (fr)
PT (1) PT2391345E (fr)
RU (1) RU2535090C2 (fr)
SG (1) SG172226A1 (fr)
TN (1) TN2011000307A1 (fr)
TW (1) TWI468191B (fr)
WO (1) WO2010086312A1 (fr)
ZA (1) ZA201104489B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (fr) * 2011-11-23 2013-05-29 PLS-Design GmbH Composition pharmaceutique pour le traitement des réactions allergiques
JP7156945B2 (ja) * 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
WO2020032227A1 (fr) * 2018-08-10 2020-02-13 キッセイ薬品工業株式会社 Granules contenant de l'oxyhydroxyde sucroferrique et composition pharmaceutique
ES2961850T3 (es) 2019-02-22 2024-03-14 Catalent Uk Swindon Zydis Ltd Minimización de la aireación de suspensiones durante la mezcla en línea
JP7543291B2 (ja) 2019-02-22 2024-09-02 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 医薬品の崩壊時間を安定させるための、保管中の薬物粒子コーティング材料の凝集を最小限に抑える
AU2020225818B2 (en) 2019-02-22 2025-09-18 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
KR20210129649A (ko) 2019-02-22 2021-10-28 카탈렌트 유.케이. 스윈던 지디스 리미티드 이부프로펜을 포함하는 약학적 조성물의 응집, 에어레이션 최소화 및 코팅 보존
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
US12208160B2 (en) 2020-07-31 2025-01-28 Catalent U.K. Swindon Zydis Limited Pharmaceutical compositions comprising coated API
CA3203975A1 (fr) 2020-12-03 2022-06-09 Battelle Memorial Institute Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
CA3216359A1 (fr) 2021-04-07 2022-10-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025105451A1 (fr) * 2023-11-17 2025-05-22 第一三共ヘルスケア株式会社 Préparation solide
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
US20070224260A1 (en) * 2004-04-15 2007-09-27 Dr. Reddy's Laboratories Limited Dosage Form Having Polymorphic Stability
ES2384637T3 (es) * 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
PT2205279E (pt) * 2007-09-28 2011-07-11 Novartis Ag Associação farmacêutica de aliscireno e valsartan

Also Published As

Publication number Publication date
PL2391345T3 (pl) 2015-03-31
RU2011135417A (ru) 2013-03-10
KR20110117199A (ko) 2011-10-26
PT2391345E (pt) 2014-12-03
CL2011001817A1 (es) 2012-01-13
WO2010086312A1 (fr) 2010-08-05
NZ593622A (en) 2013-12-20
HK1161125A1 (en) 2012-08-24
ZA201104489B (en) 2012-02-29
MX2011007779A (es) 2011-08-12
AU2010209787A1 (en) 2011-07-14
RU2535090C2 (ru) 2014-12-10
AR075179A1 (es) 2011-03-16
ES2525648T3 (es) 2014-12-26
EP2391345B1 (fr) 2014-09-03
MY153852A (en) 2015-03-31
IL213918A0 (en) 2011-07-31
CA2749531A1 (fr) 2010-08-05
ECSP11011289A (es) 2011-09-30
CN102300558A (zh) 2011-12-28
BRPI1007452A2 (pt) 2016-02-16
TW201038300A (en) 2010-11-01
SG172226A1 (en) 2011-07-28
JP2012516299A (ja) 2012-07-19
PE20110943A1 (es) 2012-01-22
CO6400184A2 (es) 2012-03-15
AU2010209787B2 (en) 2013-06-06
TWI468191B (zh) 2015-01-11
US20110287100A1 (en) 2011-11-24
EP2391345A1 (fr) 2011-12-07
TN2011000307A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
MA33060B1 (fr) Formulations galéniques de composés organiques
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
MA30807B1 (fr) Compositions pharmaceutiques.
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EP2248519A3 (fr) Formes galéniques de film non mucoadhésifs
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
EP2081550A4 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA33299B1 (fr) Nouvelle formulation de naproxène
CY1110824T1 (el) Διασπεipoμενη στο στομα φαρμακευτικη συνθεση για απο του στοματος, μεσω του στοματικου βλεννογονου ή υπογλωσσια χορηγηση αγομελατινης
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2548552A3 (fr) Ensemble de titration pour 1-amino-alkylcyclohexanes
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
EP2296654A4 (fr) Dérivés de 8-hydroxyquinoline pour le traitement d'hémopathies malignes
EP4233850A3 (fr) Formulations de capsules
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
WO2008151811A3 (fr) Procédé de fabrication d'un médicament contenant du trihydrate d'hydrochlorure de vardénafil
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA29722B1 (fr) Schema posologique pour le prasugrel
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta